8-K: Klotho Neurosciences Stockholders Approve Reverse Stock Split Proposal

Klotho Neurosciences, Inc. announced that its stockholders have approved a proposal to effect a reverse stock split of the company's common stock at a ratio between one-for-2 and one-for-50.

Summary

• At a special meeting held on May 28, 2025, Klotho Neurosciences, Inc. stockholders approved an amendment to the company's Second Amended and Restated Certificate of Incorporation.
• The approved amendment allows for a reverse stock split of the company's outstanding common stock at an exchange ratio determined by the Board of Directors, ranging from one-for-2 to one-for-50.
• On the record date of April 8, 2025, there were 28,510,632 common shares of the Company issued and outstanding.
• A quorum was present at the special meeting, with holders of 20,321,223 common shares attending in person or by proxy.
• The proposal for the Reverse Stock Split received 18,977,235 votes For, 1,343,426 votes Against, and 562 Abstentions.
• Due to sufficient votes for the Reverse Stock Split, a proposal to adjourn the meeting to solicit additional proxies was deemed moot and not voted upon.

Sentiment

Score: 7

Explanation: The successful approval of the reverse stock split proposal by shareholders is a positive step for the company, allowing it to proceed with a strategic corporate action that may be necessary for its operational or listing requirements.

Positives

• Shareholders approved the proposed reverse stock split, enabling the company to proceed with this strategic corporate action.
• The successful vote indicates shareholder alignment with the Board's decision to pursue the reverse stock split.

Negatives

• The document does not explicitly state any negative outcomes or implications of the shareholder approval itself.

Future Outlook

The company's Board of Directors is now authorized to effect a reverse stock split at an exchange ratio between one-for-2 and one-for-50, which is a future action to be implemented.

Management Comments

• Joseph Sinkule, Chief Executive Officer, signed the report on behalf of Klotho Neurosciences, Inc.

Industry Context

This filing details a company-specific corporate action (reverse stock split approval) and does not provide information on broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, with a proportional increase in the per-share price, following the reverse stock split.

Next Steps

• The Company's Board of Directors will determine the exact exchange ratio for the reverse stock split within the approved range of one-for-2 to one-for-50.
• The Company will proceed with effecting the reverse stock split.

Key Dates

Keywords

Reverse Stock Split, Shareholder Vote, Corporate Governance, SEC Filing, Klotho Neurosciences, Common Stock, Nasdaq Listing, 8-K Filing